City round-up: Aptamer; IntelliAM AI and Avacta Therapeutics
York-based life sciences business Aptamer Group has begun developing a potential rapid diagnostic test for the Bundibugyo strain of the Ebola virus as health authorities tackle the largest recorded outbreak of the rare disease in Central Africa.
The AIM-listed company is using its proprietary Optimer® technology to develop synthetic binders for a field-compatible test after outbreaks were declared in the Democratic Republic of Congo and Uganda. Existing diagnostic methods struggle to detect the Bundibugyo strain because it differs... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
